Please login to the form below

Not currently logged in
Email:
Password:

Oliver Rausch to lead translational research partnership efforts at NIHR

Has experience at UCB, GSK and Cellzome

NIHR Dr Oliver RauschDr Oliver Rausch has been appointed programme director of the UK's National Institute for Health Research translational research partnerships.

As part of the NIHR's Office for Clinical Research Infrastructure (NOCRI), the partnerships was created to support collaboration between industry, the NHS and academia in early and exploratory research for products with the potential to have a direct effect on improving healthcare.

Efforts currently cover two areas, inflammatory respiratory disease and joint and related inflammatory diseases, both of which shall be overseen by Dr Rausch.

He brings industry experience to the role having spent the past 15 years working at pharma companies across Europe.

Most recently, he was VP biology at Cellzome, and he has further experience as director, new chemical entities biology at UCB and as an investigator with GlaxoSmithKline (GSK).

Prior to joining the industry, Dr Rausch was a postdoctoral scientist at the Institute of Cancer Research in London.

“Oliver's appointment will strengthen the development of the Partnerships and underpins NOCRI's commitment to clear and streamlined access to the UK's world-leading clinical research infrastructure,” said Mark Samuels, managing director of NOCRI.

14th September 2012

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics